基于“肝为气之治”理论探讨柴胡抗肝癌作用机制的研究进展
Research Progress on the Anti Hepatoma Mechanism of Chaihu Based on the Theory of “Liver as Qi”
DOI: 10.12677/acm.2026.1693111, PDF,   
作者: 郁 雯*：黑龙江中医药大学研究生院，黑龙江 哈尔滨；刘松江#：黑龙江中医药大学附属第一医院肿瘤科，黑龙江 哈尔滨
关键词: 肝癌；柴胡；“肝为气之治”；Liver Cancer； Bupleurum chinense； “Treatment of Liver as Qi”
摘要: 肝癌作为发病率极高的恶性肿瘤之一，同样也是恶性肿瘤死亡率极高的恶性肿瘤之一，其发生发展与“肝主疏泄、调畅气机”功能失常密切相关。近年来，中医药在肝癌的治疗与预后中具有独特优势。文章基于“肝为气之治”核心理论探讨了疏肝要药“柴胡”及其主要活性成分(如柴胡皂苷A、D、B2等)抗肝癌的主要作用机制。研究发现，柴胡及其活性成分可以通过诱导肿瘤细胞凋亡、抑制增殖与细胞周期阻滞、抑制肿瘤血管生成、调节细胞自噬、改善肿瘤免疫微环境以及调控NF-κB、PI3K/AKT等关键信号通路等多种途径抑制肝癌的发生发展。为中医药抗肝癌提供新的用药思路和方法。
Abstract: In recent years, traditional Chinese medicine has unique advantages in the treatment and prognosis of liver cancer. Based on the core theory of “liver is the treatment of Qi”, this paper discusses the main mechanism of action of Bupleurum and its main active components (such as Saikosaponin A, D, B2, etc.) against liver cancer. Studies have found that Bupleurum chinense and its active components can inhibit the occurrence and development of liver cancer by inducing tumor cell apoptosis, inhibiting proliferation and cell cycle arrest, inhibiting tumor angiogenesis, regulating cell autophagy, improving tumor immune microenvironment, and regulating key signaling pathways such as NF-κB and PI3K/AKT to provide new drug ideas and methods for TCM anti liver cancer.
文章引用：郁雯, 刘松江. 基于“肝为气之治”理论探讨柴胡抗肝癌作用机制的研究进展[J]. 临床医学进展, 2026, 16(9): 831-839. https://doi.org/10.12677/acm.2026.1693111

参考文献

[1] 王鹏, 许军英, 黄浩, 等. DRG1通过调控c-Myc磷酸化促进肝癌细胞迁移和侵袭[J]. 石河子大学学报(自然科学版), 2025, 43(3): 376-86.
[2] 何凤蝶, 王秋童, 胡亚男, 等. 中国人群肝癌发病危险因素病例对照研究的meta分析[J]. 现代预防医学, 2022, 49(23): 4230-4240.
[3] 程艳婷, 李洁, 张帮, 等. 基于数据挖掘的肝癌动物模型应用分析与模型构建[J/OL]. 中国实验方剂学杂志: 1-10.
https://doi.org/10.13422/j.cnki.syfjx.20251711, 2025-07-27.
[4] 邓渊, 李向向, 石旭, 等. 中草药有效提取物通过调控铁死亡途径抑制肝细胞癌的研究进展[J]. 胃肠病学和肝病学杂志, 2025, 34(11): 1707-1711.
[5] 孙婷婷, 袁子博, 郑玉玲. 郑玉玲运用疏肝消积汤辨治原发性肝癌TACE术后经验[J/OL]. 中医学报: 1-8.
https://link.cnki.net/urlid/41.1411.R.20250901.1143.010, 2025-09-01.
[6] 韩坤余, 赵常国, 朱建平, 等. 国医大师张震“疏调气机”学术思想论治肝癌[J]. 西部中医药, 2026, 39(4): 5-8.
[7] 陈俊辉, 汪鑫, 杜思润, 等. 基于“痞坚之处, 必有伏阳”结合“肝体阴而用阳”理论探讨中医药防治肝细胞癌[J]. 中医肿瘤学杂志, 2025, 7(5): 98-105.
[8] 毛熙妍, 石清兰, 毛德文, 等. 中西医融通背景下肝主疏泄的诠释[J]. 中医药通报, 2025, 24(8): 13-17.
[9] 李华华, 赵文霞. 《伤寒杂病论》实脾理论在原发性肝癌治疗中的应用[J]. 河南中医, 2025, 45(8): 1135-1139.
[10] 黄依婷, 磨宁芳, 赵嘉欣, 等. 基于网络药理学解析舒肝方调控肝癌肠道菌群机制[J]. 医学研究杂志, 2025, 54(10): 32-39.
[11] 惠登城, 孙明瑜, 刘嘉湘. 刘嘉湘运用疏利少阳法治疗肝癌经验[J]. 国医论坛, 2021, 36(2): 56-58.
[12] 康静. 基于数据挖掘技术分析张永康教授运用小柴胡汤组方规律[D]: [硕士学位论文]. 太原: 山西中医药大学, 2021.
[13] 彭永焕, 黄学宽, 周德奇, 等. 中医药治疗结直肠癌术后复发转移的相关作用机制研究进展[J]. 中国医药科学, 2024, 14(5): 50-53.
[14] 王晓宇, 张喜召. 柴胡皂苷D调控Wnt/β-catenin信号通路改善慢性心力衰竭大鼠心肌纤维化[J]. 河南中医, 2025, 45(10): 1551-1558.
[15] 徐金铭, 王芳芳, 曹迪, 等. 柴胡及其药对的药理研究进展[J/OL]. 中华中医药学刊: 1-15.
https://link.cnki.net/urlid/21.1546.R.20250728.1644.012, 2025-07-29.
[16] 王中超, 王明珠, 张守元, 等. 中药经典名方复方制剂研究进展[J]. 亚太传统医药, 2025, 21(10): 235-240.
[17] Luo, F., Yang, J., Yang, X., Mi, J., Ye, T., Li, G., et al. (2024) Saikosaponin D Potentiates the Antineoplastic Effects of Doxorubicin in Drug-Resistant Breast Cancer through Perturbing NQO1-Mediated Intracellular Redox Balance. Phytomedicine, 133, Article 155945.
https://doi.org/10.1016/j.phymed.2024.155945
[18] Wang, X., Gan, J., Han, M., Wu, Y., Liu, L., Zhao, Y., et al. (2024) Comparison of Structure and the Synergistic Anti-Hepatocellular Carcinoma Effect of Three Polysaccharides from Vinegar-Baked Radix Bupleuri. International Journal of Biological Macromolecules, 282, Article 136755.
https://doi.org/10.1016/j.ijbiomac.2024.136755
[19] Carcy, R., Cougnon, M., Poet, M., Durandy, M., Sicard, A., Counillon, L., et al. (2021) Targeting Oxidative Stress, a Crucial Challenge in Renal Transplantation Outcome. Free Radical Biology and Medicine, 169, 258-270.
https://doi.org/10.1016/j.freeradbiomed.2021.04.023
[20] 杨丹芬, 康睿, 谢圆媛, 等. 柴胡皂苷d对哮喘小鼠气道炎症及TLR4/NF-κB通路的影响[J]. 河北医药, 2022, 44(7): 986-990+995.
[21] Zhao, J., Liu, L., Zhang, Y., Wan, Y. and Hong, Z. (2017) The Herbal Mixture Xiao-Chai-Hu Tang (XCHT) Induces Apoptosis of Human Hepatocellular Carcinoma Huh7 Cells in Vitro and in Vivo. African Journal of Traditional, Complementary and Alternative Medicines, 14, 231-241.
https://doi.org/10.21010/ajtcam.v14i3.25
[22] 有曼, 陈洁, 何广宏, 等. 柴胡皂苷b2对肝癌细胞增殖的影响及机制[J]. 中国临床药理学杂志, 2023, 39(22): 3281-3285.
[23] Shi, S., Chang, M., Liu, H., Ding, S., Yan, Z., Si, K., et al. (2022) The Structural Characteristics of an Acidic Water-Soluble Polysaccharide from Bupleurum chinense DC and Its in Vivo Anti-Tumor Activity on H22 Tumor-Bearing Mice. Polymers, 14, Article 1119.
https://doi.org/10.3390/polym14061119
[24] 王一萌, 李敬华, 田野, 等. 基于数据挖掘和网络药理学探讨中医药治疗原发性肝癌用药规律和作用机制[J]. 中国中医药图书情报杂志, 2025, 49(2): 72-77.
[25] 许严伟, 耿胜男, 王梦琪, 等. 柴胡皂苷D对阿霉素治疗小鼠肝癌的靶向导引作用[J]. 中草药, 2021, 52(3): 778-788.
[26] 张昱航, 许鹏. 从肿瘤微环境角度探讨中晚期肺癌的中医治疗[J]. 吉林中医药, 2021, 41(10): 1387-1392.
[27] 陈亮. 基于抗血管生成作用探讨中药抗肿瘤作用[J]. 中国医学创新, 2025, 22(1): 170-174.
[28] 马瑞, 高子涵, 白雪, 等. 柴胡皂苷-b2对原发性肝癌小鼠血管生成的影响[J]. 中国临床药理学杂志, 2020, 36(14): 2063-2065.
[29] Lei, C., Gao, Z., Lv, X., Zhu, Y., Li, R. and Li, S. (2023) Saikosaponin-b2 Inhibits Primary Liver Cancer by Regulating the STK4/IRAK1/NF-κB Pathway. Biomedicines, 11, Article 2859.
https://doi.org/10.3390/biomedicines11102859
[30] You, M., Fu, J., Lv, X., Wang, L., Wang, H. and Li, R. (2023) Saikosaponin B2 Inhibits Tumor Angiogenesis in Liver Cancer via Down‑Regulation of VEGF/ERK/HIF‑1α Signaling. Oncology Reports, 50, Article No. 136.
https://doi.org/10.3892/or.2023.8573
[31] Zhao, M., Ying, L., Wang, R., Yao, J., Zhu, L., Zheng, M., et al. (2021) DHX15 Inhibits Autophagy and the Proliferation of Hepatoma Cells. Frontiers in Medicine, 7, Article 591736.
https://doi.org/10.3389/fmed.2020.591736
[32] Makino, Y., Hikita, H., Fukumoto, K., Sung, J.H., Sakano, Y., Murai, K., et al. (2022) Constitutive Activation of the Tumor Suppressor P53 in Hepatocytes Paradoxically Promotes Non-Cell Autonomous Liver Carcinogenesis. Cancer Research, 82, 2860-2873.
https://doi.org/10.1158/0008-5472.can-21-4390
[33] Chu, T.H., Chan, H.H., Kuo, H.M., et al. (2014) Celecoxib Suppresses Hepatoma Stemness and Progression by Up-Regulating PTEN. Oncotarget, 5, 1475-1490.
https://doi.org/10.18632/oncotarget.1745
[34] 李洪芳. 柴胡皂苷d对HepaRG细胞CYP450酶的影响[D]: [硕士学位论文]. 遵义: 遵义医科大学, 2021.
[35] 李霞, 杨杰雄, 刘西洋, 等. 基于“正虚瘀毒”探讨免疫微环境和代谢重编程在肝癌中的作用[J]. 中国实验方剂学杂志, 2026, 32(14): 100-109.
[36] Nagarsheth, N., Wicha, M.S. and Zou, W. (2017) Chemokines in the Cancer Microenvironment and Their Relevance in Cancer Immunotherapy. Nature Reviews Immunology, 17, 559-572.
https://doi.org/10.1038/nri.2017.49
[37] 张振巍, 张娜娜, 张华, 等. 非酒精性脂肪肝中医药治疗的系统生物学研究: 配伍规律解析与多靶点协同机制[J]. 药学前沿, 2025, 29(11): 1878-1886.
[38] Zhang, F., Zhou, K., Yuan, W. and Sun, K. (2023) Radix Bupleuri-Radix Paeoniae Alba Inhibits the Development of Hepatocellular Carcinoma through Activation of the PTEN/PD-L1 Axis within the Immune Microenvironment. Nutrition and Cancer, 76, 63-79.
https://doi.org/10.1080/01635581.2023.2276525
[39] 黄家柏. 经动脉化疗栓塞术联合信迪利单抗和贝伐珠单抗治疗不可切除肝细胞癌的Ⅰb期临床试验[D]: [硕士学位论文]. 广州: 广州医科大学, 2025.
[40] Zou, X., Sui, Y., Tang, X.Y., et al. (2022) Mechanism of Bupleurum scorzonerifolium and Paeonia lactiflora Herbal Pair against Liver Cancer: An Exploration Based on UPLC-Q-TOF-MS Combined with Network Pharmacology. China Journal of Chinese Materia Medica, 47, 3597-3608.
[41] Xu, H., Huang, Y., Li, F., Liu, N., Wang, Y., Qiu, M., et al. (2025) Investigation on the Inhibitory Mechanism of Chai Hu Hua Ji Tang on Liver Cancer Based on a Network Pharmacology Analysis. Cancer Biotherapy and Radiopharmaceuticals, 40, 622-634.
https://doi.org/10.1177/10849785251372756

为你推荐